These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10370220)

  • 1. Design of a fluid energy single vessel powder processor for pharmaceutical use.
    Kay GR; Staniforth JN; Tobyn MJ; Horrill MD; Newnes LB; MacGregor SA; Li M; Atherton G; Lamming RC; Hajee DW
    Int J Pharm; 1999 Apr; 181(2):243-54. PubMed ID: 10370220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical production of tableting granules in an ultra-small-scale high-shear granulator as a pre-formulation study.
    Ogawa T; Uchino T; Takahashi D; Izumi T; Otsuka M
    Drug Dev Ind Pharm; 2012 Nov; 38(11):1390-3. PubMed ID: 22356186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving powder flow properties of a cohesive lactose monohydrate powder by intensive mechanical dry coating.
    Zhou Q; Armstrong B; Larson I; Stewart PJ; Morton DA
    J Pharm Sci; 2010 Feb; 99(2):969-81. PubMed ID: 19795479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid formulation screening with a Multipart Microscale Fluid bed Powder processor.
    Kivikero N; Murtomaa M; Antikainen O; Hatara J; Juppo AM; Sandler N
    Pharm Dev Technol; 2011 Aug; 16(4):358-66. PubMed ID: 20387990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW; Schneider M; Morrical BD; Imanidis G
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
    Zeng XM; Pandhal KH; Martin GP
    Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery.
    Zeng XM; Martin GP; Marriott C; Pritchard J
    J Pharm Sci; 2001 Sep; 90(9):1424-34. PubMed ID: 11745794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of energy indices in estimating powder compaction functionality of mixtures in pharmaceutical tableting.
    Vachon MG; Chulia D
    Int J Pharm; 1999 Jan; 177(2):183-200. PubMed ID: 10205613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
    Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
    Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preparation of budesonide sustained-release dry powder for inhalation and influence of lactose content].
    Liang ZL; Wang XH; Ni R; Zhang L; Muenster U; Mao SR
    Yao Xue Xue Bao; 2015 Sep; 50(9):1180-5. PubMed ID: 26757557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Response Surface Methodology to Estimate the Design Space of Pharmaceutical Diluents for Dispensing Powdered Formulations.
    Miyazaki Y; Takayama K; Uchino T; Kagawa Y
    Chem Pharm Bull (Tokyo); 2016; 64(12):1698-1706. PubMed ID: 27904079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of load on particle size distribution of lactose-crystalline cellulose mixed powder.
    Nakamori T; Miyagishim A; Nozawa Y; Sadzuka Y; Sonobe T
    Int J Pharm; 2008 Apr; 354(1-2):255-9. PubMed ID: 18258396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Powder Flow Testing: Judicious Choice of Test Methods.
    Tay JYS; Liew CV; Heng PWS
    AAPS PharmSciTech; 2017 Jul; 18(5):1843-1854. PubMed ID: 27844415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microscale granulation in a fluid bed powder processor using electrostatic atomisation.
    Kivikero N; Murtomaa M; Ingelbeen B; Antikainen O; Räsänen E; Mannermaa JP; Juppo AM
    Eur J Pharm Biopharm; 2009 Jan; 71(1):130-7. PubMed ID: 18703138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.